Literature DB >> 31728026

KRAS-G12C in the crosshairs.

Sarah Seton-Rogers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31728026     DOI： 10.1038/s41568-019-0228-3

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  9 in total

1.  Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.

Authors:  Pierre-Olivier Gaudreau; J Jack Lee; John V Heymach; Don L Gibbons
Journal:  Clin Lung Cancer       Date:  2020-03-04       Impact factor: 4.785

Review 2.  Anticancer drug resistance: An update and perspective.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Drug Resist Updat       Date:  2021-12-16       Impact factor: 18.500

Review 3.  Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.

Authors:  Iris Z Uras; Herwig P Moll; Emilio Casanova
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

4.  Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.

Authors:  Antonio B Ward; Adam B Keeton; Xi Chen; Tyler E Mattox; Alex B Coley; Yulia Y Maxuitenko; Donald J Buchsbaum; Troy D Randall; Gang Zhou; Gary A Piazza
Journal:  MedComm (Beijing)       Date:  2020-06-25

5.  Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.

Authors:  Luiz Henrique Araujo; Bianca Mendes Souza; Laura Rabelo Leite; Sabrina A F Parma; Natália P Lopes; Frederico S V Malta; Maíra C M Freire
Journal:  BMC Cancer       Date:  2021-02-25       Impact factor: 4.430

6.  Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models.

Authors:  Long Chen; Jing Zhang; Xinjing Wang; Yu Li; Lu Zhou; Xiongxiong Lu; Guoqiang Dong; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2021-07-19       Impact factor: 11.413

7.  Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

Authors:  Honglin Jiang; Ryan K Muir; Ryan L Gonciarz; Adam B Olshen; Iwei Yeh; Byron C Hann; Ning Zhao; Yung-Hua Wang; Spencer C Behr; James E Korkola; Michael J Evans; Eric A Collisson; Adam R Renslo
Journal:  J Exp Med       Date:  2022-03-09       Impact factor: 17.579

8.  Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer.

Authors:  Hiroyuki Sayama; Diana Marcantonio; Takeyuki Nagashima; Masashi Shimazaki; Tsuyoshi Minematsu; Joshua F Apgar; John M Burke; Lucia Wille; Yasuhisa Nagasaka; Daniel C Kirouac
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-26

9.  Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.

Authors:  Dorna Varshavi; Dorsa Varshavi; Nicola McCarthy; Kirill Veselkov; Hector C Keun; Jeremy R Everett
Journal:  Metabolomics       Date:  2020-04-16       Impact factor: 4.290
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.